Myristoleic acid

Name: Myristoleic acid
Brand: MedChemExpress
SKU: HY-113332
Rating: 4.5 (1 reviews)

Cat. No.: HY-113332 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.

For research use only. We do not sell to patients.

Myristoleic acid Chemical Structure

CAS No. : 544-64-9

Size	Price	Stock	Quantity
100 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Myristoleic acid:

Myristoleate sodium Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells^[1].

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells^[1].
Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Human prostatic carcinoma LNCaP cells.
Concentration:	0, 50, 100, 150, 200, 250 μg/mL.
Incubation Time:	24 h.
Result:	When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.

In Vivo

Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice at 5 weeks^[2].
Dosage:	0.2, 2 mg/kg
Administration:	IP every 24 h for 4 days.
Result:	Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.

Molecular Weight

226.36

Formula

C₁₄H₂₆O₂

CAS No.

544-64-9

Appearance

Liquid (Density: 0.9 g/cm³)

Color

Colorless to light yellow

SMILES

CCCC/C=C\CCCCCCCC(O)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Animals

Microorganisms

enterococci

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (441.77 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 100 mg/mL (441.77 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.4177 mL	22.0887 mL	44.1774 mL
5 mM	0.8835 mL	4.4177 mL	8.8355 mL
10 mM	0.4418 mL	2.2089 mL	4.4177 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% PBS
Solubility: 10 mg/mL (44.18 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (5.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (5.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (5.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (268 KB) SDS (393 KB)

COA (238 KB) HNMR (253 KB)

Handling Instructions (2659 KB)

References

[1]. Xiaoyan Gao, et al. Ozone initiated heterogeneous oxidation of unsaturated carboxylic acids by ATR-FTIR spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2019 May 5;214:177-183. [Content Brief]

[2]. Jun-Oh Kwon, et al. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2. Eur J Pharmacol. 2015 Dec 5;768:189-98. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	4.4177 mL	22.0887 mL	44.1774 mL	110.4435 mL
	5 mM	0.8835 mL	4.4177 mL	8.8355 mL	22.0887 mL
	10 mM	0.4418 mL	2.2089 mL	4.4177 mL	11.0444 mL
	15 mM	0.2945 mL	1.4726 mL	2.9452 mL	7.3629 mL
	20 mM	0.2209 mL	1.1044 mL	2.2089 mL	5.5222 mL
	25 mM	0.1767 mL	0.8835 mL	1.7671 mL	4.4177 mL
	30 mM	0.1473 mL	0.7363 mL	1.4726 mL	3.6815 mL
	40 mM	0.1104 mL	0.5522 mL	1.1044 mL	2.7611 mL
	50 mM	0.0884 mL	0.4418 mL	0.8835 mL	2.2089 mL
	60 mM	0.0736 mL	0.3681 mL	0.7363 mL	1.8407 mL
	80 mM	0.0552 mL	0.2761 mL	0.5522 mL	1.3805 mL
	100 mM	0.0442 mL	0.2209 mL	0.4418 mL	1.1044 mL